News

Boosting regenerative medicine
Enlarge image

FundingUKGermanySpainNetherlands

Boosting regenerative medicine

30.05.2012 - Regenerative medicine centres foster their translational approach. An international initiative formed in Germany, a new centre is opened in Scotland.

Edinburgh/Enschede/Seville/Berlin/Toronto – The Scottish Centre for Regenerative Medicine (SCRM) officially started operations on May 28. The SCRM will conduct cutting-edge stem cell research to find new therapies for Multiple Sclerosis, Parkinson’s disease, motor neuron disease and heart and liver disease. Up to 250 scientists will work at the centre, which is funded by the University of Edinburgh, the Medical Research Council, Scottish Enterprise and the British Heart Foundation with up to £54m. The SCRM will put an special emphasis on translational efforts, turning laboratory discoveries faster into treatments. An additional newly founded £24m bioincubator, named „Nine, Edinburgh Bioquarter“ offers lab and office space to start-up ventures and established biotech companies.

Just days before, the Regenerative Medicine Coalition constituted itself in Germany’s capital city Berlin. Six translational medicine centres from Europe and North America joined forces to push stem cell based medicine forward. The Berlin-Brandenburg Centre for Regenerative Therapies (BRCT, Berlin, Germany), the Centre for Commercialisation of Regenerative Medicine (Toronto, Canada), the MIRA Institute for Biomedical Technology and Technical Medicine (Enschede, The Netherlands), the Andalusian Molecular Biology and Regenerative Medicine Centre (Seville, Spain), the McGowan Institute of Regenerative Medicine (Pittsburgh, USA) and the Institute for Regenerative Medicine (Winston Salem, USA) are among the founding members. „We plan to jointly tackle projects in order to accelerate the development of therapies”, announced Frank Lauter from BRCT.

http://www.european-biotechnology-news.com/news/news/2012-02/boosting-regenerative-medicine.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • 4SC5.75 EUR6.28%
  • WILEX5.43 EUR3.43%

FLOP

  • CYTOS1.17 CHF-7.87%
  • MEDIGENE9.45 EUR-6.99%
  • FORMYCON24.99 EUR-5.02%

TOP

  • 4SC5.75 EUR285.9%
  • WILEX5.43 EUR78.0%
  • SARTORIUS151.95 EUR18.3%

FLOP

  • BIOTEST70.10 EUR-26.1%
  • MEDIGENE9.45 EUR-16.7%
  • CYTOS1.17 CHF-14.6%

TOP

  • SANTHERA93.40 CHF2294.9%
  • CYTOS1.17 CHF735.7%
  • WILEX5.43 EUR531.4%

FLOP

  • MOLOGEN4.79 EUR-56.5%
  • BIOFRONTERA2.39 EUR-26.2%
  • THERAMETRICS0.08 CHF-20.0%

No liability assumed, Date: 06.05.2015